Mirikizumab-Induced Transcriptome Changes in Ulcerative Colitis Patient Biopsies at Week 12 Are Maintained Through Week 52

INTRODUCTION: Mirikizumab, an anti-interleukin-23p19 monoclonal antibody, demonstrated efficacy in phase 2 and 3 randomized clinical trials of patients with moderate-to-severe ulcerative colitis (UC). Previous results have shown that 12 weeks of mirikizumab treatment downregulated transcripts associ...

Descripción completa

Detalles Bibliográficos
Autores principales: Johnson, Travis, Steere, Boyd, Zhang, Pengyue, Zang, Yong, Higgs, Richard, Milch, Catherine, Reinisch, Walter, Panés, Julian, Huang, Kun, D'Haens, Geert, Krishnan, Venkatesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10684203/
https://www.ncbi.nlm.nih.gov/pubmed/37594044
http://dx.doi.org/10.14309/ctg.0000000000000630

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10684203/
https://www.ncbi.nlm.nih.gov/pubmed/37594044
http://dx.doi.org/10.14309/ctg.0000000000000630

Ejemplares similares